Translationally, our findings also suggest that targeting HP1γ stability using HDAC1 inhibitor resensitizes the anti-MM effect of PIs in resistant MM cells, which may benefit the management of relapse or refractory MM patients. The gene discussed is HDAC1; the disease is Miyoshi myopathy.